Li Xiang, Rhee David K, Malhotra Rajeev, Mayeur Claire, Hurst Liam A, Ager Emily, Shelton Georgia, Kramer Yael, McCulloh David, Keefe David, Bloch Kenneth D, Bloch Donald B, Peterson Randall T
J Clin Invest. 2016 Jan;126(1):389-401. doi: 10.1172/JCI83831. Epub 2015 Dec 14.
Iron homeostasis is tightly regulated by the membrane iron exporter ferroportin and its regulatory peptide hormone hepcidin. The hepcidin/ferroportin axis is considered a promising therapeutic target for the treatment of diseases of iron overload or deficiency. Here, we conducted a chemical screen in zebrafish to identify small molecules that decrease ferroportin protein levels. The chemical screen led to the identification of 3 steroid molecules, epitiostanol, progesterone, and mifepristone, which decrease ferroportin levels by increasing the biosynthesis of hepcidin. These hepcidin-inducing steroids (HISs) did not activate known hepcidin-inducing pathways, including the BMP and JAK/STAT3 pathways. Progesterone receptor membrane component-1 (PGRMC1) was required for HIS-dependent increases in hepcidin biosynthesis, as PGRMC1 depletion in cultured hepatoma cells and zebrafish blocked the ability of HISs to increase hepcidin mRNA levels. Neutralizing antibodies directed against PGRMC1 attenuated the ability of HISs to induce hepcidin gene expression. Inhibiting the kinases of the SRC family, which are downstream of PGRMC1, blocked the ability of HISs to increase hepcidin mRNA levels. Furthermore, HIS treatment increased hepcidin biosynthesis in mice and humans. Together, these data indicate that PGRMC1 regulates hepcidin gene expression through an evolutionarily conserved mechanism. These studies have identified drug candidates and potential therapeutic targets for the treatment of diseases of abnormal iron metabolism.
铁稳态由膜铁输出蛋白铁转运蛋白及其调节肽激素铁调素严格调控。铁调素/铁转运蛋白轴被认为是治疗铁过载或铁缺乏疾病的一个有前景的治疗靶点。在此,我们在斑马鱼中进行了化学筛选,以鉴定能降低铁转运蛋白水平的小分子。化学筛选鉴定出3种甾体分子,表睾酮、孕酮和米非司酮,它们通过增加铁调素的生物合成来降低铁转运蛋白水平。这些诱导铁调素的甾体(HISs)并未激活已知的诱导铁调素的途径,包括骨形态发生蛋白(BMP)和JAK/STAT3途径。孕酮受体膜成分-1(PGRMC1)是HIS依赖的铁调素生物合成增加所必需的,因为在培养的肝癌细胞和斑马鱼中耗尽PGRMC1会阻断HISs增加铁调素mRNA水平的能力。针对PGRMC1的中和抗体减弱了HISs诱导铁调素基因表达的能力。抑制PGRMC1下游的SRC家族激酶,会阻断HISs增加铁调素mRNA水平的能力。此外,HIS处理可增加小鼠和人类的铁调素生物合成。总之,这些数据表明PGRMC1通过一种进化上保守的机制调节铁调素基因表达。这些研究已经鉴定出用于治疗铁代谢异常疾病的候选药物和潜在治疗靶点。